Anavex Life Sciences

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anavex Life Sciences reports Q1 results, highlights precision medicine focus

Anavex Life Sciences showcased positive results in the Alzheimer's study and emphasized precision medicine in addressing neurological disorders.
The company's financial performance, with a net loss of $13 million and a cash position of $143.6 million, reflects ongoing research and development efforts.
Challenges include financial losses, regulatory discussions, and operational complexities, while opportunities lie in upcoming data readouts and new clinical trials.
Overall, Anavex's strategic focus on precision medicine and diverse pipeline position it for potential growth and advancements in neurological treatments.

Anavex Life Sciences reports Q2 results, eyes pipeline expansion

Anavex Life Sciences reported a mixed financial performance in Q2 2023 but maintains a strong cash position for future operations and clinical programs.
The company's focus on Alzheimer's disease treatments, pipeline expansion, and team strengthening reflect a commitment to advancing innovative therapies.
While facing financial challenges and competitive pressures, Anavex has opportunities to leverage its clinical successes, new hires, and partnerships for future growth.

Anavex Life Sciences reports Q3 loss, eyes neurology breakthroughs

Anavex Life Sciences is actively pursuing clinical advancements in neurology with a focus on blarcamesine. Despite financial challenges, the company's strategic partnerships and pipeline expansion position it well for future growth and innovation.

Anavex Life Sciences reports strong cash position amidst strategic focus

Anavex Life Sciences demonstrated financial strength with a substantial cash position in Q4 2023, while facing challenges with a net loss.
The company's strategic focus on precision medicine programs and ongoing trials presents opportunities for growth and innovation in the healthcare sector.
Navigating regulatory processes and balancing financial sustainability will be key for Anavex to capitalize on its strengths and address operational challenges.

Anavex Life Sciences reports Q1 loss but advances precision medicine

Anavex Life Sciences reported financials reflecting a net loss but with a solid cash position, emphasizing fiscal responsibility and ongoing research progress.
The company's strengths lie in its financial stability, innovative precision medicine focus, and commitment to addressing neurological disorders.
Challenges include managing financial losses, meeting regulatory timelines, and balancing fiscal prudence with research investments.
Opportunities arise from upcoming submissions, precision medicine trends, therapeutic expansion, and potential collaborations.

Anavex Life Sciences reports Q2 progress amidst analyst inquiries

Anavex Life Sciences is actively pursuing the development of therapies for various neurological disorders. The company faces challenges in FDA guidance interpretation, European filings, and commercialization strategies. However, with a solid cash position and a focus on transformative therapies, Anavex has significant growth opportunities.

Anavex Life Sciences reports Q3 results, advances precision medicine

Anavex Life Sciences showcased financial stability with a strong cash position despite reporting a net loss, underlining their commitment to advancing treatments for brain disorders.
Progress in trials for blarcamesine in Alzheimer's disease and other neurological conditions signals potential breakthroughs in precision medicine.
While facing challenges such as managing losses and regulatory uncertainties, Anavex remains poised to leverage opportunities through upcoming data releases and regulatory submissions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Anavex Life Sciences Corp. ("Anavex Life Sciences") (NASDAQ:AVXL) concerning possible violations of federal securities laws. On December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD).

Did Anavex Life Sciences Corp. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- AVXL

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled at 1:30 PM (ET) on Monday, March 4th, 2024, at the Boston Marriott Copley Place in Boston, MA.

Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference

Anavex Life Sciences Corp. (AVXL) Q1 2024 Earnings Call Transcript

Company to host a webcast today at 8:30 a.m. Eastern Time

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 530.7% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade

ADMA Biologics

Ekso Bionics Hlds

Inhibikase Therapeutics

ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.

New Strong Buy Stocks for January 31st

Eldorado Gold

MongoDB

PagerDuty

IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.

New Strong Buy Stocks for January 26th

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, findings from the ANAVEX®3-71 first-in-human study which achieved its safety objectives. The publication is entitled, ‘Population-Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease'.1 The publication reports the Population-based characterization of the Pharmacokinetics (PK) and food effect of ANAVEX®3-71 as part of the single ascending dose study in healthy participants with the primary objective of assessing dose proportionality of ANAVEX®3-71, and to characterize the effect of food on the PK of ANAVEX®3-71.

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

Canadian Imperial Bank of Commerce

Potbelly

ADMA, PBPB, YPF, CM and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 24, 2023.

New Strong Buy Stocks for January 24th

Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024 Trial to include Schizophrenia validated clinical outcomes PANSS and EEG/ERP biomarkers Trial to study positive, negative, and cognitive domains of Schizophrenia based on ANAVEX®3-71's ability to synergistically activate both SIGMAR1 and M1 muscarinic receptors NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and schizophrenia, today announced the initiation of the U.S. FDA cleared placebo-controlled Phase 2 trial of ANAVEX®3-71 for the treatment of schizophrenia, which is expected to begin in Q2 2024. ANAVEX®3-71 positive initial Phase 1 results in healthy volunteers were previously reported.1 ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects.

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Anavex (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions

AC Immune

Akoya Biosciences Inc

Getaround Inc

GRIFFIN RLTY TRUST INC

Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.

5 Small-Cap Stocks to Play the January Effect

Grant of Its Newest U.S. Patent Expands Anavex's Intellectual Property Portfolio in Neurologic Indications Grant of Its Newest U.S. Patent Expands Anavex's Intellectual Property Portfolio in Neurologic Indications

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

Anavex Life Sciences (NASDAQ:AVXL) shares plunged this week on mixed results from its Rett Syndrome clinical study but analysts at Dawson James still see the stock as a worthwhile investment.  The company reported topline results from its Phase 2/3 EXCELLENCE study in pediatric Rett Syndrome which had enrolled 92 patients aged from five to 17 years.

Anavex Life Sciences shares tank on Rett Syndrome trial results but analysts remain positive

Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.

Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Anavex's President and Chief Executive Officer, Christopher U Missling, PhD, is scheduled to present at the conference at the Westin St. Francis in San Francisco, CA on January 11, 2024 at 10:30am Pacific Standard Time (PST).

Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

Significant activation of key developmental and metabolic gene pathways and potential compensatory mechanism with ANAVEX®2-73 in Rett syndrome patients Significant activation of key developmental and metabolic gene pathways and potential compensatory mechanism with ANAVEX®2-73 in Rett syndrome patients

Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome

NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, announced today that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) agreed that oral blarcamesine for Alzheimer's disease is eligible for submission of an application for a Union Marketing Authorisation in the EU under the European Medicines Agency's centralised procedure.

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease

The average of price targets set by Wall Street analysts indicates a potential upside of 401.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Anavex Life Sciences (AVXL) Have the Potential to Rally 401.47% as Wall Street Analysts Expect?

Annovis Bio

Biogen

INmune Bio Inc

Eli Lilly

Cassava Sciences Inc

Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, Green Valley's GV-971, aromatherapy, and panax ginseng not only inhibit the formation of oxidants but scavenge them and reverse part of their damage.

Alzheimer's Disease Drug Development: Another Lost Year

The mean of analysts' price targets for Anavex Life Sciences (AVXL) points to a 468.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 468.83% Upside in Anavex Life Sciences (AVXL): Can the Stock Really Move This High?

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q4 2023 Earnings Call Transcript November 27, 2023 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Trading Tom Bishop - Bishop Research Operator Good morning, and welcome to the Anavex Life Sciences Fiscal 2023 Fourth Quarter Conference Call. My name is Clint Tomlinson and I will be your host for today's call.

News for Anavex Life Sciences Stock (AVXL)